Characteristics of Products of Fibrinogen Origin in the Presence of Anti- SARS-CoV-2 IgG in the Bloodstream

Page: [69 - 75] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: The hemostasis system has been extensively investigated in patients in the acute phase of coronavirus disease 2019 (COVID-19). In contrast, the post-COVID syndrome is a poorly known entity, and there is a lack of information on the mechanisms underlying the hemostasis abnormalities in the post-COVID period.

Aim: To analyze the potential changes in the parameters of the hemostasis system in the post- COVID period in the plasma of donors with different titers of anti-SARS-CoV-2 IgG.

Methods: The plasma from 160 donors who had recovered from COVID infection was used in the study. Based on the results of the Abbott SARS-CoV-2 IgG serological assay, all donors were divided into several groups: 5 ± 3 (n = 20); 55 ± 5 (n = 20); 65 ± 5 (n = 20); 75 ± 5 (n = 20); 85 ± 5 (n = 20); 95 ± 5 (n = 20); 125 ± 5 (n = 20); 175 ± 5 (n = 20) Index (S/C). A total of 20 healthy individuals without anti-SARS-CoV-2 IgG constituted the control group. Key laboratory parameters, such as fibrinogen concentrations, soluble fibrin monomer complex (SFMCs), and Ddimer, were investigated. In addition, the qualitative composition of the fraction of SFMCs was analyzed.

Results: The slight increase in the concentration of fibrinogen, SFMCs, and D-dimers in some donor groups have been found, which could cause the development of hemostasis disorders. In the fraction of SFMCs, the increase in the number of protein fragments with a molecular weight of less than 250 kDa and an increase in the level of proteins with a molecular weight of more than 270 kDa was revealed.

Conclusion: The obtained results indicated the relationship between the changes in the parameters of the hemostasis system and the titers of anti-SARS-CoV-2 IgG in donors in the post-COVID period. It can be assumed that donors with higher titers of anti-SARS-CoV-2 IgG (>55 ± 5 Index (S/C)) are more prone to hemostasis abnormalities in the post-COVID period since a pronounced imbalance in the levels of SFMCs and D-dimer characterizes them. The appearance of protein fragments of different molecular weights in the fraction of SFMC points to uncontrolled activation of biochemical processes involving molecules of fibrinogenic origin. Additional studies are required to elucidate the role of anti-SARS-CoV-2 IgG in the post-COVID period.

Graphical Abstract

[1]
Falalyeyeva T, Pellicano R. Hot topics in chronic inflammation-induced diseases at the time of COVID-19. Minerva Biotechnol Biomol Res 2021; 33(2): 51-2.
[http://dx.doi.org/10.23736/S2724-542X.21.02803-0]
[2]
Falalyeyeva T, Komisarenko I, Yanchyshyn A, et al. Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: A critical view during COVID-19 time. Minerva Biotechnol Biomol Res 2021; 33(2): 65-75.
[http://dx.doi.org/10.23736/S2724-542X.21.02766-X]
[3]
Aggarwal M, Dass J, Mahapatra M. Hemostatic abnormalities in COVID-19: An update. Indian J Hematol Blood Transfus 2020; 36(4): 616-26.
[http://dx.doi.org/10.1007/s12288-020-01328-2] [PMID: 32837053]
[4]
Ulanowska M, Olas B. Modulation of hemostasis in covid-19; Blood platelets may be important pieces in the COVID-19 puzzle. Pathogens 2021; 10(3): 370.
[http://dx.doi.org/10.3390/pathogens10030370] [PMID: 33808640]
[5]
Kasinathan G, Sathar J. Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review. Ann Med Surg (Lond) 2020; 56: 173-7.
[http://dx.doi.org/10.1016/j.amsu.2020.06.035] [PMID: 32637095]
[6]
Vinayagam S, Sattu K. SARS-CoV-2 and coagulation disorders in different organs. Life Sci 2020; 260: 118431.
[http://dx.doi.org/10.1016/j.lfs.2020.118431] [PMID: 32946915]
[7]
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7.
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[8]
Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med 2020; 48(9): 1358-64.
[http://dx.doi.org/10.1097/CCM.0000000000004458] [PMID: 32467443]
[9]
Marynenko T, Halenova T, Raksha N, et al. Coagulation markers in patients with coronary artery disease. J Biol Res 2022; 95(1)
[http://dx.doi.org/10.4081/jbr.2022.10259]
[10]
Lecompte T, Hardy M, Michaux I, Dive A, Mullier F. Could daily monitoring of fibrin related markers help suspect a thrombotic event in COVID-19 patients? A prospective pilot study. TH Open 2021; 5(2): e152-4.
[http://dx.doi.org/10.1055/s-0041-1728722] [PMID: 34007953]
[11]
Bull BS, Hay KL. A macrophage attack culminating in microthromboses characterizes COVID 19 pneumonia. Immun Inflamm Dis 2021; 9(4): 1336-42.
[http://dx.doi.org/10.1002/iid3.482] [PMID: 34231951]
[12]
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. Thromb Haemost 2014; 111(2): 354-64.
[http://dx.doi.org/10.1160/TH13-06-0509] [PMID: 24172938]
[13]
Naranjo L, Ostos F, Gil-Etayo FJ, et al. Presence of extra-criteria antiphospholipid antibodies is an independent risk factor for ischemic stroke. Front Cardiovasc Med 2021; 8: 665741.
[http://dx.doi.org/10.3389/fcvm.2021.665741] [PMID: 34012984]
[14]
Katrii T, Shandyuk V, Vovk T, et al. Effect of IgG from multiple sclerosis patients on amidolytic activity of coagulation and anticoagulation factors of hemostasis. Biomed Res Ther 2017; 4(08): 1502-12.
[http://dx.doi.org/10.15419/bmrat.v4i08.205]
[15]
Katrii T, Raksha N, Halenova T, et al. Effects of IgG from the serum of ischemic stroke patients on hemostasis. J Biol Res 2021; 94(1)
[16]
Surabhi J, Shuhasini H, Gunjan KB, Narayan A. Fibrinogen in covid 19-interpreting from current evidence. J Adv Med 2021; 9(1): 5-10.
[17]
Maamar M, Artime A, Pariente E, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: A cross-sectional study. Curr Med Res Opin 2022; 1-9.
[18]
Yakovlev S, Medved L. Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes. Thromb Res 2018; 162: 93-100.
[http://dx.doi.org/10.1016/j.thromres.2017.11.007] [PMID: 29175090]
[19]
Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021; 20(1): 172.
[http://dx.doi.org/10.1186/s12933-021-01359-7] [PMID: 34425843]